Abstract:Malcolm Begg, 1 J Nicole Hamblin, 1 Emily Jarvis, 2 Glyn Bradley, 3 Stephen Mark, 4 David Michalovich, 5 Mark Lennon, 6 Hannah E Wajdner, 5 Augustin Amour, 5 Robert Wilson, 1 Ken Saunders, 5 Rikako Tanaka, 7 Saki Arai, 7 Teresa Tang, 8 Cedric Van Holsbeke, 9 Jan De Backer, 9 Wim Vos, 9 Ingrid L Titlestad, 10 J Mark FitzGerald, 11 Kieran Killian, 12 Jean Bourbeau, 13 Claude Poirier, 14 François Maltais, 15 Anthony Cahn, 1 Edith M Hessel 1 1 Refractory Respiratory Inflammation Discovery Performance Unit, GlaxoSmithKline, Stevenage, UK; 2 Biostatistics, GlaxoSmithKline R&D, Stevenage, UK; 3 Computational Biology, Medicinal Science and Technology, GlaxoSmithKline, Stevenage, UK; 4 Study Management, Clinical Development, GlaxoSmithKline, Mississauga, ON, Canada; 5 Adaptive Immunity Research Unit, GlaxoSmithKline, Stevenage, UK; 6 Nonclinical and Translational Statistics, GlaxoSmithKline, Stevenage, UK; 7 Data Management & Strategy, Clinical Development, GlaxoSmithKline, Tokyo, Japan; 8 Pharma Safety, Clinical Development, GlaxoSmithKline, Brentford, Middlesex, UK; 9 FLUIDDA nv, Kontich, 2550, Belgium; 10 Department of Respiratory Medicine, Odense University Hospital and University of Southern Denmark, Odense, Denmark; 11 Centre for Heart and Lung Health, University of British Columbia, Vancouver, BC, Canada; 12 Cardiorespiratory Research Laboratory, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada; 13 Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, QC, Canada; 14 Department of Medicine, Respiratory Medicine Division, University of Montreal, Montreal, QC, Canada; 15 Institut Universitaire de Cardiologie et de Pneumologie de Québe, Université Laval, Quebec City, QC, Canada Correspondence: Malcolm Begg Refractory Respiratory Inflammation Discovery Performance Unit, GlaxoSmithKline, Stevenage, Herts, UK Email Background: Inhibition of phosphoinositide 3-kinase δ (PI3Kδ) exerts corrective effects on the dysregulated migration characteristics of neutrophils isolated from patients with chronic obstructive pulmonary disease (COPD). Objective: To develop novel, induced sputum endpoints to demonstrate changes in neutrophil phenotype in the lung by administering nemiralisib, a potent and selective inhaled PI3Kδ inhibitor, to patients with stable COPD or patients with acute exacerbation (AE) of COPD. Methods: In two randomized, double-blind, placebo-controlled clinical trials patients with A) stable COPD (N=28, randomized 3:1) or B) AECOPD (N=44, randomized 1:1) received treatment with inhaled nemiralisib (1mg). Endpoints included induced sputum at various time points before and during treatment for the measurement of transcriptomics (primary endpoint), inflammatory mediators, functional respiratory imaging (FRI), and spirometry. Results: In stable COPD patients, the use of nemiralisib was associated with alterations in sputum neutrophil transcriptomics suggestive of an improvement in migration phenotype; however, the same nemiralisib-evoked effects were not observed in AECOPD. Inhibition of sputum inflammatory mediators was also observed in stable but not AECOPD patients. In contrast, a placebo-corrected improvement in forced expiratory volume in 1 sec of 136 mL (95% Credible Intervals − 46, 315mL) with a probability that the true treatment ratio was > 0% (Pr(θ> 0)) of 93% was observed in AECOPD. However, FRI endpoints remained unchanged. Conclusion: We provide evidence for nemiralisib-evoked changes in neutrophil migration phenotype in stable COPD but not AECOPD, despite improving lung function in the latter group. We conclude that induced sputum can be used for measuring evidence of alteration of neutrophil phenotype in stable patients, and our study provides a data set of the sputum transcriptomic changes during recovery from AECOPD. Keywords: nemiralisib, sputum, transcriptomics, COPD exacerbations, PI3Kdelta The mechanisms of action of novel immunomodulator drugs are far removed from established clinical efficacy endpoints, hence translational endpoints are helpful to build confidence in the pharmacology of the drug and enables better interpretation of study outcomes. We set out to explore the consequence of treatment with the inhaled phosphoinositide 3-kinase δ (PI3Kδ) inhibitor nemiralisib, which was administered to patients suffering from -Abstract Truncated-

Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis

Advances in the Discovery of Novel Inhaled PI3K Inhibitors for the Treatment of Asthma

Inhalation of Itraconazole Mitigates Bleomycin-Induced Lung Fibrosis Via Regulating SPP1 and C3 Signaling Pathway Pivotal in the Interaction Between Phagocytic Macrophages and Diseased Fibroblasts

PI3Kγδ inhibition suppresses key disease features in a rat model of asthma

A nonnatural peptide targeting the A-kinase anchoring function of PI3Kγ for therapeutic cAMP modulation in pulmonary cells

Pre-clinical proof-of-concept of anti-fibrotic activity of caveolin-1 scaffolding domain peptide LTI-03 in precision cut lung slices from patients with Idiopathic Pulmonary Fibrosis

Effects of Phosphoinositide 3-Kinase on Protease-Induced Acute and Chronic Lung Inflammation, Remodeling, and Emphysema in Rats

Discovery of CHF-6523, an Inhaled Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease

A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF-β Signaling and Activation of cAMP/PKA Signaling

Innovative Pre-Clinical Data Using Peptides to Intervene in the Evolution of Pulmonary Fibrosis

CHF6523 data suggest that the phosphoinositide 3-kinase delta isoform is not a suitable target for the management of COPD

Development and Evaluation of ABI-171, a New Fluoro-Catechin Derivative, for the Treatment of Idiopathic Pulmonary Fibrosis

Investigation into the anti-airway inflammatory role of the PI3Kγ inhibitor JN-PK1: An in vitro and in vivo study

The antipsychotic agent flupentixol is a new PI3K inhibitor and potential anticancer drug for lung cancer

Discovery of 4-Methylquinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis.

Discovery of Highly Selective and Orally Bioavailable PI3Kδ Inhibitors with Anti-Inflammatory Activity for Treatment of Acute Lung Injury.

Casein Kinase 1δ/ε Inhibitor, PF670462 Attenuates the Fibrogenic Effects of Transforming Growth Factor-β in Pulmonary Fibrosis

Exploring PI3Kδ Molecular Pathways in Stable COPD and Following an Acute Exacerbation, Two Randomized Controlled Trials

Glycogen Synthase Kinase-3 Inhibition by CHIR99021 Promotes Alveolar Epithelial Cell Proliferation and Lung Regeneration in the Lipopolysaccharide-Induced Acute Lung Injury Mouse Model

Nintedanib Ameliorates Bleomycin-Induced Pulmonary Fibrosis, Inflammation, Apoptosis, and Oxidative Stress by Modulating PI3K/Akt/mTOR Pathway in Mice

Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury